Ocugen Agrees to Sell OCU400 Rights in Australia, New Zealand and the ASEAN Region

Ocugen agreed to sell Celairis Therapeutics exclusive commercialization rights to OCU400 in Australia, New Zealand and the ASEAN region. The agreement would give the Australian biopharma rights to the gene therapy candidate across those areas. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.